Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 5,241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Germ Cell Neoplasms Clear all
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

NCT01638676
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, Metformin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 15, 2026, 4:36 PM EST
Completed Early Phase 1 Interventional Results available

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

NCT03834740
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma of Brain
Interventions
Ribociclib, Everolimus
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Nov 15, 2026, 4:36 PM EST
Withdrawn Phase 1 Interventional

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

NCT01130623
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
Interventions
Pazopanib (GW786034)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 15, 2026, 4:36 PM EST
Completed No phase listed Observational

Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

NCT03438279
View directory record Official record
Conditions
Melanoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Nov 15, 2026, 4:36 PM EST
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

NCT01609790
View directory record Official record
Conditions
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Trebananib
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
243
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 172 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Nov 15, 2026, 4:36 PM EST
Completed Phase 1 Interventional

Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma

NCT03084640
View directory record Official record
Conditions
Malignant Melanoma
Interventions
CMP-001, Pembrolizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 15, 2026, 4:36 PM EST
Terminated Phase 1 Interventional

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

NCT04489420
View directory record Official record
Conditions
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents
Interventions
CYNK001-IV, CYNK001-IT
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Nov 15, 2026, 4:36 PM EST
Terminated Phase 2 Interventional Results available

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

NCT03724968
View directory record Official record
Conditions
Metastatic Melanoma, Advanced Melanoma, Metastatic Melanoma Stratified by MHC-II Expression
Interventions
Nivolumab, Relatlimab, Ipilimumab
Drug
Lead sponsor
Elizabeth Davis
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Nov 15, 2026, 4:36 PM EST
Completed Not applicable Interventional

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

NCT02857374
View directory record Official record
Conditions
Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis, Sentinel Lymph Node Biopsy
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Nov 15, 2026, 4:36 PM EST
Completed Phase 1 Interventional

Fluorescence Guided Resection of Brain Tumors

NCT00870779
View directory record Official record
Conditions
Brain Tumors
Interventions
5-aminolevulinic acid
Drug
Lead sponsor
David W. Roberts
Other
Eligibility
21 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Nov 15, 2026, 4:36 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

NCT06146920
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer
Interventions
Evaluation of ctDNA using the F1T after 1 year of immunotherapy
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 15, 2026, 4:36 PM EST
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

NCT00462982
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Nov 15, 2026, 4:36 PM EST
Completed Phase 1 Interventional

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

NCT00644696
View directory record Official record
Conditions
Neuroblastoma
Interventions
Irinotecan and Bortezomib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Nov 15, 2026, 4:36 PM EST
Terminated Phase 2 Interventional Results available

High Dose IL-2 in Combination With Anti-PD-1

NCT03991130
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Metastatic
Interventions
IL-2 and Nivolumab
Drug
Lead sponsor
Gregory Daniels
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 15, 2026, 4:36 PM EST
Completed No phase listed Observational

Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy

NCT01777802
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Lung Cancer, Melanoma
Interventions
SBRT, IMRT, Brachytherapy
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Nov 15, 2026, 4:36 PM EST
Completed Phase 1Phase 2 Interventional

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

NCT00871481
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
ipilimumab, cyclophosphamide, biopsy, aldesleukin, immunohistochemistry staining method, polymerase chain reaction, immunoenzyme technique, therapeutic cytotoxic T lymphocytes
Biological · Drug · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Nov 15, 2026, 4:36 PM EST
Completed Phase 1 Interventional

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

NCT02082665
View directory record Official record
Conditions
Cancer
Interventions
Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Nov 15, 2026, 4:36 PM EST
Terminated Phase 2 Interventional Results available

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

NCT01159067
View directory record Official record
Conditions
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
Interventions
deferasirox
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Nov 15, 2026, 4:36 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

NCT04464759
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Hydroxychloroquine, Ipilimumab
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 15, 2026, 4:36 PM EST
Completed No phase listed Observational

Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families

NCT00341627
View directory record Official record
Conditions
Chordoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 110 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
2
States / cities
Iowa City, Iowa • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Nov 15, 2026, 4:36 PM EST
Active, not recruiting Phase 2 Interventional

Proton Beam Therapy for Chordoma Patients

NCT00496119
View directory record Official record
Conditions
Chordoma
Interventions
Proton Beam Therapy, Photon Beam Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 15, 2026, 4:36 PM EST
Terminated No phase listed Observational

Feasibility and Functionality of fPAM Imaging in Melanoma

NCT00776945
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 15, 2026, 4:36 PM EST
Not yet recruiting Phase 2 Interventional

Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma

NCT07735819
View directory record Official record
Conditions
Low Grade Glioma, Glioblastoma
Interventions
Minocycline 200mg/day, [18F]FETrp PET/CT
Drug · Diagnostic Test
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 15, 2026, 4:36 PM EST
Active, not recruiting Phase 2 Interventional Results available

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

NCT03149029
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Pembrolizumab, Dabrafenib, Trametinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 15, 2026, 4:36 PM EST